All In Biotech

Drug Trial Radar · NCT07899047

Albumin-Bound Paclitaxel (Ⅱ) in Patients With Advanced Breast Cancer

Efficacy, Safety, and Cost-Effectiveness of Albumin-Bound Paclitaxel (Ⅱ) in Chinese Patients With Advanced Breast Cancer: A Multicenter, Observational, Real-World Study

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

1,372

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

May 2030

Study completion May 2030

Sponsor

Sponsor type
Academic, hospital or other
First posted
Oct 27, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, prospective, observational real-world study. The study aims to evaluate the efficacy, safety and economic benefits of albumin-bound paclitaxel (Ⅱ) compared with conventional albumin-bound paclitaxel, in patients with HER2-negative advanced breast cancer.

Conditions

  • Breast Cancer
  • HER2-negative Breast Cancer
  • Advanced Breast Cancer

Interventions

  • Experimental GroupDrug

    Regimens containing paclitaxel for injection (albumin bound) (Ⅱ)

  • control groupDrug

    Regimens containing paclitaxel for injection (albumin bound)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: 42 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.